. 2020 Mar 16;9(3):802. doi: 10.3390/jcm9030802

Table 1.

Cytogenetic and molecular profile of prognostic-risk groups.

Prognostic-Risk Group	Cytogenetic Aberrations and Molecular Abnormalities
Favorable	t(8:21)(q22;q22) AML1(RUNX1)-ETO(RUNX1T1) inv(16)(p13;1q22)CBFα-MYH11 t(15;17)(q22;q12)PML-RARα NPM1 mutation without FLT3-ITD or with FLT3-ITD^low * CEBPA biallelic mutations
Intermediate	NPM1 mutation with FLT3-ITD^high * NPM1 wild-type without FLT3-ITD or with FLT3-ITD^low * (in the absence of adverse risk genetic lesions) t(9;11)(p22;q23)MLLT3-KMT2A Other cytogenetic abnormalities not included in the other groups
Adverse	t(6;9)(p23;q34)DEK/NUP214 inv(3)(q21;q26.2)GATA2,MECOM(EVI1) t(9;22)(q34.1;q11.2)BCR-ABL1 t(v;11q23.3)KMT2A(MLL) rearranged −5 or del(5q) −7 or del(7q) abn(17p) Complex karyotype Monosomal karyotype NPM1 wild-type and FLT3-ITD^high * RUNX1 mutations (in the absence of favorable risk genetic lesions) ASXL1 mutations (in the absence of favorable risk genetic lesions) TP53 mutations

* Low, low allelic ratio (<0.5); * high, high allelic ratio (≥0.5).